Roche blindsided by off-label Avastin fallout in India

Emily Wasserman Roche, maker of pricey wet age-related macular degeneration drug Lucentis, has long railed against countries' moves to use its cancer drug Avastin off-label for ...

Roche and AbbVie line up for quick approval for cancer drug venetoclax

Damian Garde Partners Roche and AbbVie are speeding toward FDA approval with a cancer treatment tabbed as a potential blockbuster, picking up a priority review for a blood cancer therapy. FierceBiotech ...

With Roche in the rear view mirror, Constellation Pharma grabs $55M round

John Carroll FierceBiotech News

Roche backs €19M CNS round; CRUK puts £20M into cancer vax; In womb stem cell trial to start

Nick Paul Taylor In this week's EuroBiotech Report, Ysios Capital led a €19.4 million ($ 21.7 million) investment in Minoryx Therapeutics with the support of Roche Venture ...

Roche dumps its cancer drug R&D pact with Wilex

John Carroll Roche is bowing out of a two-year-old collaboration with a subsidiary of a struggling Wilex. FierceBiotech News

Roche neighbors sue, claiming contamination lowered home prices

Carly Helfand Roche handled hazardous chemicals at its now-shuttered facility in Nutley, NJ–and its neighbors say the company didn't do it properly. FiercePharma News

Residents want to sue Roche before it gives up New Jersey campus

Eric Palmer Roche closed its Clifton, NJ, campus in 2013 and hopes to be free of the property this year. But some area residents want to slap the Swiss drugmaker with a lawsuit before ...

Roche and Exelixis roll toward FDA approval with a melanoma cocktail

Damian Garde Roche and Exelixis are one step closer to FDA approval for their skin cancer-treating combination treatment, as the agency has accepted their application and promised a ...

Roche boasts new Lucentis approval for retinal damage in diabetes

Carly Helfand Roche now has another approval under its belt for eye drug Lucentis. And it’s in a market it can call its own: Lucentis is the first U.S.-approved treatment for ...

Roche bets $545M on Trophos’ once-failed orphan drug

Damian Garde Roche has signed a deal to trade up to €470 million ($ 545 million) for Trophos, a company at work on a mid-stage treatment for the rare and debilitating spinal muscular ...

With Roche out the door, Chiasma is raising $56M to go it alone

Damian Garde In early 2013, Roche signed a $ 595 million deal with Israel's Chiasma with eyes on its promising treatment for the hormone disorder acromegaly. But the Swiss drugmaker ...

Roche builds CLL case for Gazyva in two-horse race with GSK

Emily Wasserman Roche won FDA approval for a supplemental license application of its chronic lymphocytic leukemia drug Gazyva, strengthening its case over rival GlaxoSmithKline and ...
Page 1 of 712345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS